急性病患儿接受市售类血浆等渗液体治疗时电解质紊乱风险:一项随机临床试验
该研究在芬兰奥卢大学医院儿科急诊开展非盲随机实用试验,纳入614例6月龄至12岁需住院静脉补液的急性病患儿。结果显示,接受市售类血浆等渗液体(钠140 mmol/L、钾5 mmol/L)的患儿临床显著电解质紊乱发生率为20%,显著高于接受中度低渗液体(钠80 mmol/L、钾20 mmol/L)的2.9%(差异95%CI 12%-22%,P<.001),风险增加6.7倍,主要为低钾血症;等渗组体重增加也更明显(平均279 vs 195 g,95%CI 16-154 g,P=.02)。
要点
- 急性病患儿使用类血浆等渗液体(钾5 mmol/L)较中度低渗液体(钾20 mmol/L)显著增加电解质紊乱风险,主要为低钾血症。
- 等渗组临床显著电解质紊乱发生率为20%,低渗组为2.9%,风险增加6.7倍。
- 等渗组体重增加更多(平均279 vs 195 g),提示液体潴留风险。
核心结论
- 在急性病住院患儿中,市售类血浆等渗液体治疗较既往广泛使用的中度低渗液体(含钾20 mmol/L)显著增加临床显著电解质紊乱风险,主要为低钾血症。
研究设计与样本
- 非盲随机临床实用试验,2016年10月3日至2019年4月15日在芬兰奥卢大学医院儿科急诊开展,纳入614例6月龄至12岁因急性病住院需静脉补液的患儿,按意向治疗分析。
主要发现
- 等渗组临床显著电解质紊乱发生率为20%(61/308),低渗组为2.9%(9/306),差异95%CI 12%-22%,P<.001。
- 等渗组发生低钾血症57例(19%),高钠血症4例(1.3%)。
- 等渗组体重增加大于低渗组(平均279 vs 195 g,95%CI 16-154 g,P=.02)。
- 等渗组发生电解质紊乱的风险是低渗组的6.7倍。
关键数值与推荐
- 临床显著电解质紊乱定义为住院期间低钾血症<3.5 mmol/L、高钠血症>148 mmol/L或低钠血症<132 mmol/L。
- 等渗液体成分为钠140 mmol/L、钾5 mmol/L的5%葡萄糖溶液;中度低渗液体为钠80 mmol/L、钾20 mmol/L的5%葡萄糖溶液。
临床怎么用
- 急性病患儿静脉补液时,应警惕市售类血浆等渗液体(钾5 mmol/L)相关低钾血症和高钠血症风险,并关注体重变化。
- 选择液体时需权衡电解质紊乱风险,中度低渗液体(含钾20 mmol/L)在本研究中电解质紊乱风险更低。
局限性
- 研究为非盲设计,可能引入偏倚。
- 研究对象均为芬兰语儿童,外推性受限。
- 部分分析为探索性事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The use of isotonic fluid therapy is currently recommended in children, but there is limited evidence of optimal fluid therapy in acutely ill children. OBJECTIVE: To evaluate the risk for electrolyte disorders, including hyponatremia, hypernatremia, and hypokalemia, and the risk of fluid retention in acutely ill children receiving commercially available plasmalike isotonic fluid therapy. DESIGN, SETTING, AND PARTICIPANTS: This unblinded, randomized clinical pragmatic trial was conducted at the pediatric emergency department of Oulu University Hospital, Finland, from October 3, 2016, through April 15, 2019. Eligible study subjects (N = 614) were between 6 months and 12 years of age, required hospitalization due to an acute illness, and needed intravenous fluid therapy. Exclusion criteria included a plasma sodium concentration of less than 130 mmol/L or greater than 150 mmol/L on admission; a plasma potassium concentration of less than 3.0 mmol/L on admission; clinical need of fluid therapy with 10% glucose solution; a history of diabetes, diabetic ketoacidosis, or diabetes insipidus; a need for renal replacement therapy; severe liver disease; pediatric cancer requiring protocol-determined chemotherapy hydration; and inborn errors of metabolism. All outcomes and samples size were prespecified except those clearly marked as exploratory post hoc analyses. All analyses were intention to treat. INTERVENTIONS: Acutely ill children were randomized to receive commercially available plasmalike isotonic fluid therapy (140 mmol/L of sodium and 5 mmol/L potassium in 5% dextrose) or moderately hypotonic fluid therapy (80 mmol/L sodium and 20 mmol/L potassium in 5% dextrose). MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of children with any clinically significant electrolyte disorder, defined as hypokalemia less than 3.5 mmol/L, hypernatremia greater than 148 mmol/L, or hyponatremia less than 132 mmol/L during hospitalization due to acute illness. The main secondary outcomes were the proportion of children with severe hypokalemia and weight change. RESULTS: There were 614 total study subjects (mean [SD] age, 4.0 [3.1] years; 315 children were boys [51%] and all 614 were Finnish speaking [100%]). Clinically significant electrolyte disorder was more common in children receiving plasmalike isotonic fluid therapy (61 of 308 patients [20%]) compared with those receiving moderately hypotonic fluid therapy (9 of 306 patients [2.9%]; 95% CI of the difference, 12%-22%; P < .001). The risk of developing electrolyte disorder was 6.7-fold greater in children receiving isotonic fluid therapy. Hypokalemia developed in 57 patients (19%) and hypernatremia developed in 4 patients (1.3%) receiving plasmalike isotonic fluid therapy. Weight change was greater in children receiving isotonic, plasmalike fluid therapy compared with those receiving mildly hypotonic fluids (mean weight gain, 279 vs 195 g; 95% CI, 16-154 g; P = .02). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, commercially available plasmalike isotonic fluid therapy markedly increased the risk for clinically significant electrolyte disorders, mostly due to hypokalemia, in acutely ill children compared with previously widely used moderately hypotonic fluid therapy containing 20 mmol/L of potassium. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02926989.
引用
- Lehtiranta S, Honkila M, Kallio M, et al. Risk of Electrolyte Disorders in Acutely Ill Children Receiving Commercially Available Plasmalike Isotonic Fluids: A Randomized Clinical Trial. JAMA Pediatr. 2021. PMID: 33104176. doi:10.1001/jamapediatrics.2020.3383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。